home / stock / ksphf / ksphf news
Summary In terms of product sales, RIGL has been a one drug company with Tavalisse in immune thrombocytopenia. The recent approval of Rezlidhia opens the door for investors to track the growth of another drug, a new source of excitement. The potential for sales growth with Tavalisse...
Summary RIGL hoped to expand the label of its drug Tavalisse (fostamatinib), but the failure of the drug in phase 3 appeared to scupper its chances. RIGL sought guidance to see if a reanalysis of the failed phase 3 study might be well received, but it doesn't appear it was. Th...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biopharmaceutical company ObsEva (NASDAQ: OBSV ) is trending today, but not necessarily in a good way. The company issued a corporate update press release early this morning. It seems that ObsEva is having review is...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ObsEva (NASDAQ: OBSV ) stock is on the move this morning after the Swiss biopharma reported positive results from trials of its Yselty treatment for uterine fibroids. OBSV stock was up 5.65% in pre-market trading...